Related Experiment Video

Updated: Oct 18, 2026

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest
04:55

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest

Published on: May 26, 2023

The hemodynamic effects of propofol in children with congenital heart disease

G D Williams1, T K Jones, K A Hanson

  • 1Department of Anesthesiology, University of Washington School of Medicine and Children's Hospital and Regional Medical Center, Seattle 98105, USA.

Anesthesia and Analgesia
|December 10, 1999
PubMed

Insights

Propofol decreases systemic vascular resistance in children with congenital heart defects. This can alter cardiac shunt flow and cause arterial desaturation in those with cyanotic heart disease.

Area of Science:

  • Pediatric Cardiology
  • Anesthesiology
  • Cardiovascular Physiology

Background:

  • Congenital heart disease (CHD) presents diverse hemodynamic challenges in pediatric populations.
  • Propofol is a common anesthetic agent used in pediatric procedures, including cardiac catheterization.
  • Understanding propofol's effects in children with CHD is crucial for safe anesthetic management.

Purpose of the Study:

  • To investigate the hemodynamic effects of propofol in pediatric patients undergoing cardiac catheterization.
  • To assess how propofol influences systemic and pulmonary hemodynamics in children with varying types of congenital heart defects and shunts.
  • To evaluate changes in cardiac shunt direction and pulmonary-to-systemic flow ratio following propofol administration.

Main Methods:

  • A prospective study involving 30 children with congenital heart disease undergoing elective cardiac catheterization.
  • Patients were categorized into three groups based on the presence and type of cardiac shunt (no shunt, left-to-right, right-to-left).
  • Hemodynamic parameters and oxygen consumption were measured before and after propofol administration (bolus and infusion), with statistical comparisons using paired t-tests.

Main Results:

  • Propofol significantly decreased systemic mean arterial pressure and systemic vascular resistance, while increasing systemic blood flow across all patient groups.
  • Pulmonary vascular resistance and heart rate remained unchanged; however, the pulmonary-to-systemic resistance ratio increased.
  • In patients with shunts, propofol decreased left-to-right flow and increased right-to-left flow, leading to a significant decrease in the pulmonary-to-systemic flow ratio.
  • Group III patients (right-to-left shunt) experienced clinically significant decreases in arterial oxygen saturation (Sao2) and partial pressure of oxygen (Pao2).

Conclusions:

  • Propofol administration in children with congenital heart defects primarily reduces systemic vascular resistance.
  • This reduction can alter the direction and magnitude of blood flow through cardiac shunts.
  • The findings highlight a potential risk of arterial desaturation in cyanotic heart disease patients due to propofol-induced hemodynamic changes.
Abstract

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...